Illustration: AI-generated · Inside China AI
Fourier: The World’s Most Innovative Humanoid Startup Wants to Care for You
Part of China’s Humanoid Seven — our complete guide to the seven companies that define China’s humanoid industry.
When LexisNexis published its patent-strength ranking of the world’s humanoid robotics start-ups in late July 2026, the top spot did not go to a Silicon Valley name. It went to Fourier, a Shanghai company that most European readers have never heard of — with a quality-weighted portfolio of 149 patents, ahead of every US competitor. Fourier’s route to that position is one of the most distinctive in the industry: it did not start with humanoids at all.
From rehabilitation to humanoids
Alex Gu founded Fourier (then Fourier Intelligence) in Shanghai in 2015, after years of building rehabilitation robots. The company’s first products were an upper-limb rehab robot and, in 2017, the Fourier X1 — described as mainland China’s first commercial lower-limb exoskeleton. That clinical heritage still defines the company: Fourier says it has served more than 2,000 medical institutions and enterprise clients in over 40 countries. In December 2023, Xi Jinping visited the company — a signal of how seriously Beijing takes the intersection of robotics and healthcare.
The GR series: humanoids built for care
Fourier’s humanoid line began with the GR-1 in 2023, followed by the GR-2 in 2024. The current flagship GR-3, which made its US debut at CES in January 2026, shows where the company is heading: a 165 cm “care-bot” with 31 distributed pressure sensors, soft upholstered surfaces, hot-swappable batteries and a dual-path interaction system combining rules with a large language model — designed for eldercare, hospitals and public service rather than factory floors. While competitors chase industrial deployments, Fourier is positioning for the sector with the most acute demographic need.
Key numbers
- No. 1 worldwide in LexisNexis’ Patent Asset Index for humanoid start-ups (July 2026), with 149 quality-weighted patents
- 2,000+ medical institutions and clients in 40+ countries served since the rehab era
- Funding rounds backed by SoftBank Vision Fund 2 and Saudi Aramco’s Prosperity7 Ventures, including a ~¥800 million Series E in January 2025
- International branches in Singapore and Malaysia, with hospital partnerships including Sunway Medical Centre
Why Fourier matters
Patents are a leading indicator: they show where a company will be defensible in five years, not where it is today. Fourier topping a quality-weighted global ranking — the same methodology that puts US firms ahead on average patent quality — suggests China’s humanoid lead is not only about manufacturing scale but increasingly about foundational technology. And Fourier’s care focus targets the one humanoid market whose demand curve is demographically guaranteed.
The European angle
Europe is the world’s fastest-ageing continent after Japan, with a care-worker shortage that grows every year — precisely the problem the GR-3 is built for. Fourier already operates internationally through its healthcare network, but has no visible European base yet. For European hospital groups, care providers and medtech investors, Fourier is worth watching now, before its care robots reach CE-marked reality: the regulatory pathway for care robotics in the EU is unwritten, and the companies that engage early will help define it.
No responses yet